Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: A systematic review and meta-analysis

Chest

Volumn 142, Issue 2, 2012, Pages 401-411

  Janda, Surinder ^a   Swiston, John ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DEOXYRIBONUCLEASE; PLACEBO; STREPTOKINASE; UROKINASE;

ARTICLE; FIBRINOLYTIC THERAPY; HUMAN; LENGTH OF STAY; META ANALYSIS; MORTALITY; PARANEUMONIC EFFUSION; PARAPNEUMONIC EFFUSION; PLEURA EFFUSION; PLEURA EMPYEMA; PLEURISY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 84864799182     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-3071     Document Type: Article

References (41)

1. Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the USA. Thorax. 2011;66(8):663-668.
2. Light RW. Parapneumonic effusions and empyema. Clin Chest Med. 1985;6(1):55-62.
3. Light RW. A new classification of parapneumonic effusions and empyema. Chest. 1995;108(2):299-301.
4. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg. 2007;133(2):346-351.
5. Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. The clinical course and management of thoracic empyema. QJM. 1996;89(4):285-289.
6. Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med. 1999;160(5 pt 1):1682-1687.
7. Maskell NA, Davies CW, Nunn AJ, et al;First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352(9):865-874.
8. Tillett WS, Sherry S, Read CT. The use of streptokinase-streptodornase in the treatment of chronic empyema;with an interpretive discussion of enzymatic actions in the field of intrathoracic diseases. J Thorac Surg. 1951;21(4):325-341.
9. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med. 1999;159(1):37-42.
10. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax. 1997;52(5):416-421.
11. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med. 2004;170(1):49-53.
12. Tokuda Y, Matsushima D, Stein GH, Miyagi S. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest. 2006;129( 3): 783-790.
13. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2008 ;( 2):CD002312.
14. Davies HE, Davies RJ, Davies CW;BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(suppl 2):ii41-ii53.
15. Moher D, Liberati A, Tetzlaff J, Altman DG;PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 ; 151:264-269, W64.
16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org. Accessed January 2012.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
21. Chung CL, Chen CH, Yeh CY, Sheu JR, Chang SC. Early effective drainage in the treatment of loculated tuberculous pleurisy. Eur Respir J. 2008;31(6):1261-1267.
22. Cases Viedma E, Lorenzo Dus MJ, González-Molina A, Sanchis Aldás JL. A study of loculated tuberculous pleural effusions treated with intrapleural urokinase. Respir Med. 2006;100(11):2037-2042.
23. Kwak SM, Park CS, Cho JH, et al. The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study. Yonsei Med J. 2004;45(5):822-828.
24. Talib SH, Verma GR, Arshad M, Tayade BO, Rafeeque A. Utility of intrapleural streptokinase in management of chronic empyemas. J Assoc Physicians India. 2003;51: 464-468.
25. Ding D, Deng Q, Zhang H. The study of intrapleural urokinase in the prevention of pleural thickening and loculated effusions by tuberculous pleurisy [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2001;24(1):32-34.
26. Bouros D, Schiza S, Patsourakis G, Chalkiadakis G, Panagou P, Siafakas NM. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med. 1997;155(1):291-295.
27. Tuncozgur B, Ustunsoy H, Sivrikoz MC, et al. Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. Int J Clin Pract. 2001;55( 10): 658-660.
28. Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Lioulias A. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. Eur J Cardiothorac Surg. 2005;28(4):599-603.
29. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526.
30. Temes RT, Follis F, Kessler RM, Pett SB Jr, Wernly JA. Intrapleural fibrinolytics in management of empyema thoracis. Chest. 1996;110(1):102-106.
31. Hippocrates. The Genuine Works of Hippocrates: The Classics of Surgery. Birmingham, AL: Gryphon Editions;1985: 768-771.
32. Heffner JE, Klein JS, Hampson C. Diagnostic utility and clinical application of imaging for pleural space infections. Chest. 2010;137(2):467-479.
33. Shankar S, Gulati M, Kang M, Gupta S, Suri S. Image-guided percutaneous drainage of thoracic empyema: can sonography predict the outcome? Eur Radiol. 2000;10(3):495-499.
34. Ali I, Unruh H. Management of empyema thoracis. Ann Thorac Surg. 1990;50(3):355-359.
35. Ashbaugh DG. Empyema thoracis. Factors influencing morbidity and mortality. Chest. 1991;99(5):1162-1165.
36. Rahman NM, Maskell NA, Davies CW, et al. The relationship between chest tube size and clinical outcome in pleural infection. Chest. 2010;137(3):536-543.
37. Walker CA, Shirk MB, Tschampel MM, Visconti JA. Intrapleural alteplase in a patient with complicated pleural effusion. Ann Pharmacother. 2003;37(3):376-379.
38. Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. Chest. 1997;111(6):1548-1551.
39. Light RW, Nguyen T, Mulligan ME, Sasse SA. The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung. 2000;178(1):13-18.
40. Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest. 2000;117(6):1728-1733.
41. Maskell NA, Gleeson FV. Images in clinical medicine. Effect of intrapleural streptokinase on a loculated malignant pleural effusion. N Engl J Med. 2003;348(14):e4.